No Data
12 Health Care Stocks Moving In Thursday's After-Market Session
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
Travere Therapeutics Receives Swiss Regulator's Temporary Marketing Approval for Kidney Disease Treatment
Express News | CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of Filspari® (Sparsentan) for the Treatment of Iga Nephropathy
CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy
Travere Therapeutics Initiated at Sector Outperform by Scotiabank